CE18 - Innovation biomédicale

Pan-Cancer Imaging and Killing Strategy – PanCaiKS

Submission summary

Currently, standard cancer treatment includes surgery, external radiotherapy, and chemotherapy and / or immunotherapy. However, despite all the progress made in recent decades, there are still serious clinical situations offering very few or no therapeutic options to patients, leaving them with a survival limited to a few months in the case of cancers associated with a poor prognosis. There is therefore an urgent need for new treatment lines and, from this perspective, vectorized internal radiotherapy seems promising. It delivers a toxic dose of radioactivity directly to tumor cells while preserving healthy tissue. This requires the specific targeting of tumor cells: among the possible vectors, peptides are powerful tools since they are chemically accessible and can be easily modified to construct radiotherapies specific to a cell target. The PanCAIKS project aims to develop targeted radiotherapy agents based on peptides directed specifically to an original receptor (Peptide Receptor RadioTherapy, PRRT) to treat cancers with a poor prognosis (for example, pancreatic, liver and triple breast tumors. negative or gliomas.

Project coordination

Philippe KAROYAN (Sorbonne Université)

The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.

Partner

CEMCA CHIMIE, ELECTROCHIMIE MOLECULAIRES ET CHIMIE ANALYTIQUE
LBM Sorbonne Université
K-Pharma
FONDAT REGION OUEST LIGUE CANCER
GUERBET
PARCC Institut national de la sante et de la recherche medicale

Help of the ANR 569,649 euros
Beginning and duration of the scientific project: January 2023 - 48 Months

Useful links

Explorez notre base de projets financés

 

 

ANR makes available its datasets on funded projects, click here to find more.

Sign up for the latest news:
Subscribe to our newsletter